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And the musculoskeletal health of older adults
Background
The scientific literature related to vitamin D and bone health 
in older adults is extensive. 
Objective
This article aims to summarise key practice points regarding 
vitamin D and bone health in older adults, relevant to general 
practitioners, and to provide an overview of the background 
literature to enable GPs to appreciate the extent of the 
supporting evidence.
Discussion
Vitamin D supplementation can prevent falls, particularly in 
the vitamin D deficient elderly. However, adequate vitamin 
D levels and dietary calcium intake are needed for effective 
primary fracture prevention with greatest benefits occurring 
in the elderly with vitamin D deficiency and/or low dietary 
calcium intakes. For secondary fracture prevention, ie. 
preventing further fractures in the elderly who have already 
sustained a fragility fracture, specific anti-osteoporosis 
treatment is necessary. However, to maximise the benefits of 
these medications, vitamin D deficiency should be corrected 
and adequate dietary calcium consumed.
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Vitamin D is frequently used as a generic term to describe 
a number of specific molecules (Table 1). Vitamin D3 is 
formed through the action of ultraviolet light on precursors 
in the skin, and this is also the main form of vitamin D 
found in supplements available in Australia. Vitamin D2 is 
produced from by ultraviolet (UV) irradiation of the plant 
steroid, ergosterol. Vitamin D3 and D2 are metabolised to 
25-hydroxyvitamin D [25(OH)D] in the liver and serum 
25(OH)D is used to assess vitamin D status. The biologically 
active form of vitamin D responsible for its endocrine 
functions for maintaining calcium homeostasis is produced 
by further hydroxylation in the kidney to 1,25-(OH)2D. 
However, the vitamin D receptor is expressed in many 
tissues and many extra-renal tissues have the capacity 
to make 1,25(OH)2D, so vitamin D also appears to have 
autocrine and paracrine pathways of action.1 
Levels necessary for bone health
the threshold for the level of vitamin D to optimise a range of health 
outcomes remains controversial and randomised controlled trial evidence 
to support aiming for high levels is very limited. For bone health and 
muscle function, the optimal level appears to be ≥50 or 60 nmol/l, using 
the higher value if measured in summer to allow for seasonal decrease.1 
A cut-off of 50 nmol/l remains appropriate to define deficiency,1,2 with 
further classification into severe (<12.5 nmol/l), moderate (12.5–29 
nmol/l) and mild (30–50 nmol/l) deficiency.1 
Seasonal variability
At a population level, 25(oh)D levels can be described with a 
sinusoidal curve. there is substantial seasonal variability, with 25(oh)
D levels at the end of summer being around 20–35 nmol/l higher than 
at the end of winter.3 there are as yet no data of which the authors are 
aware that relate the duration of deficiency, that is the proportion of 
time in a given year spent under a threshold of 50 nmol/l, and health 
outcomes. nonetheless, it is critical to take into account the time of 
year that a patient’s 25(oh)D level is measured when interpreting 
vitamin D levels and making management choices. For example, a 
patient who is mildly vitamin D deficient at the end of summer will 
most likely be deficient all year round, and the deficiency will become 
more severe during winter. therefore vitamin D supplementation might 
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Osteoporosis, falls and fracture
Key messages
For maximal primary fracture prevention in the elderly, 
adequate vitamin D levels and dietary calcium intake are 
both needed. 
The benefits of supplementation are likely to be greater in 
those with vitamin D deficiency and/or low dietary calcium 
intakes.
low bone mineral density and falls are both risk factors for 
osteoporotic fractures.11 serum vitamin D has been shown to be 
associated with both these risk factors in observational studies. 
in cross-sectional studies, serum vitamin D in the range 30–90 
be needed. in contrast, for someone who is mildly deficient at the end 
of winter, a suggestion to slightly increase sun exposure at appropriate 
times of the day might be sufficient. 
Vitamin D and muscle function
muscle weakness can be a sign of vitamin D deficiency.4 the 
mechanism of this is unclear. it has been postulated that effects 
are mediated through actions of 1,25(oh)2D on vitamin D-specific 
nuclear receptor in muscle tissue,5 but the presence of such receptors 
has recently been questioned.6 Regardless of mechanism, poor 
muscle function from vitamin D deficiency may impact further on 
musculoskeletal health by predisposing to higher falls risk with 
resulting fracture (see later section). there is evidence in older adults 
that vitamin D affects factors directly related to muscle strength and 
function.5 this includes prospective data demonstrating that elderly 
men and women with baseline serum 25(oh)D levels <25 nmol/l, were 
2.57 times more likely to lose >40% of their grip strength and over 3% 
of their muscle mass over a 3 year period.7 A recent meta-analysis of 17 
randomised controlled trials (Rcts) involving 5072 adults demonstrated 
improvements in muscle strength only with vitamin D supplementation 
in studies in which the mean baseline 25(oh)D level of participants 
was <25 nmol/l (four studies, 465 participants),8 suggesting that most 
benefit is obtained in people with moderate to severe deficiency. 
Vitamin D related osteomalacia
osteomalacia is a bone disorder in adults in which osteoid, the 
newly formed bone matrix, does not mineralise. clinical symptoms 
include bone pain, muscular weakness (particularly proximal muscle 
weakness) and difficultly with walking.9 Fractures may occur due to 
bone fragility. Radiological changes also include pseudofractures 
(looser’s zone, Figure 1), which appear as a radiolucent line through 
bone cortex often with marginal sclerosis. Vitamin D deficiency is one 
cause of osteomalacia but vitamin D levels usually need to be very 
low (<25 nmol/l, often <12.5 nmol/l),9 to cause clinical osteomalacia. 
other causes of osteomalacia include very low calcium intake and 
hyposphataemia from a range of causes. Furthermore, older adults 
consuming inadequate dietary calcium with low serum vitamin D 
levels can develop both osteoporosis and osteomalacia,2 although 
the precise prevalence of osteomalacia in patients with hip fracture 
is unclear due to substantial differences in how osteomalacia is 
histologically defined in different studies.10 
Table 1. Specific molecules often included under the generic term ‘vitamin D’
Vitamin D3 (cholecalciferol) Formed in skin from UV exposure and main form found in vitamin D 
supplements
Vitamin D2 (ergocalciferol) Produced by UV irradiation of the plant steroid ergosterol. Found in 
some supplements
25-hydroxyvitamin D [25(OH)D] Produced in liver from vitamin D2 and D3
Serum level used to measure vitamin D status
1,25 dihydroxyvitamin D [1,25-(OH)2D] (calcitriol) Biologically active form of vitamin D, produced by hydroxylation of 
25(OH)D by kidneys
Figure 1. Looser’s zone (pseudofracture) in osteomala-
cia. There is a radiolucent line through the medial right 
femoral cortex with some sclerosis at its margins
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nmol/l has been positively correlated with hip bone mineral density 
in the elderly,12 but no clear threshold value has been established 
beyond which the relationship disappears. most Rcts with bone 
density outcomes have given calcium and vitamin D concurrently, 
and overall effects on bone mineral density have predominantly 
been modest and mostly occurred in the first year of treatment. low 
serum vitamin D has also been associated with falls in observational 
studies.13,14 importantly, this association has been confirmed by 
Rct data. A meta-analysis of Rcts of vitamin D supplementation 
in the elderly (whether community dwelling or in institutions) 
demonstrated a reduction in falls risk of 19% with doses of vitamin D 
of 700–1000 iu/day (pooled relative risk [RR] 0.81; 95% ci: 0.71–0.92 
from seven studies, n=1921) with no effects at lower doses (two 
studies, n=505).15 in addition, a subgroup analysis showed a 23% 
risk reduction (pooled RR 0.77; 95% ci: 0.65–0.90) if serum 25(oh)
D levels above 60 nmol/l were achieved, but no reduction in risk 
if achieved levels were <60 nmol/l. consistent with this, a meta-
analysis of studies performed only in community dwelling older 
people demonstrated a reduction in falls-risk only in studies whose 
participants were selected on the basis of low serum vitamin D16 and 
a separate meta-analysis of studies in older people in nursing care 
facilities or hospitals showed a reduction in rate of falls.17 one more 
recent Rct has raised concerns regarding the safety of intermittent 
mega doses of vitamin D in the elderly, as such a regimen increased 
falls and fracture risk18 (see adverse affects of vitamin D).
Given that vitamin D may exert effects through improved muscle 
function and falls risk reduction and bone density effects, substantial 
weight in clinical decision making needs to be given to studies with 
fracture outcomes as endpoints, so as to encompass the possible 
benefits or detriments of the full range of vitamin D effects. there 
is also potential for an interplay between calcium intake and 
vitamin D with very low levels of calcium intake causing secondary 
hyperparathyroidism with increased 1,25(oh)2D which in turn may 
cause increased breakdown of 25(oh)D.10 
several systematic reviews have addressed the interplay of 
calcium and vitamin D on fracture outcomes (Table 2). tang et al19 
reviewed trials of calcium or calcium in combination with vitamin 
D. in 17 trials with over 52 000 participants, in trials giving calcium 
alone there was no statistically significant decrease in fracture risk 
but in trials of calcium and vitamin D given in combination there 
was a statistically significant 13% risk reduction. Furthermore, in 
the subgroup of studies where vitamin D was co-administered, a 
dose in excess of 800 iu/day was needed to produce an effect (risk 
reduction of 16%). Greater effects were seen studies with a low 
mean baseline serum vitamin D (Table 1), although the p-value of 
0.06 for the difference in effects was not statistically significant. 
no difference in effect size was seen if a cut-off of 50 nmol/l was 
used. this suggests that benefits were more pronounced with more 
severe levels of vitamin D deficiency. unsurprisingly, in studies in 
which compliance with treatment was high (>80%), the risk reduction 
was more marked at 24%.18 other meta-analyses have compared the 
effects of vitamin D alone compared to vitamin D given with calcium 
on fracture risk20–22 and consistently demonstrated that for there to be 
a reduction in fracture risk, it is necessary that vitamin D and calcium 
are administered together and that vitamin D alone is insufficient to 
reduce fracture risk. Again, the potential for intermittent mega-dose 
vitamin D supplementation to result in increased falls and fracture 
should be noted.18
The role of vitamin D and calcium in 
secondary fracture prevention
Key messages
Vitamin D and calcium supplementation alone are 
inadequate for secondary fracture prevention. But optimal 
vitamin D levels and adequate calcium intake are needed 
to maximise effectiveness of anti-resorptive therapy for 
preventing further fractures.
Table 2. Fracture risk reduction from meta- 
analyses of RCTs of vitamin D alone and of vitamin 
D combined with calcium*
All fractures Relative risk
Tang, 200719
Calcium alone (n=6517) RR 0.90 (0.80–1.00)a
Calcium and vitamin D (n=46 108) RR 0.87 (0.77–0.97)
 Vitamin D <800 IU/day (n=36 671) RR 0.87 (0.71–1.05)b
 Vitamin D ≥800 IU/day (n=9437) RR 0.84 (0.75–0.94)
 Serum 25(OH)D <25 nmol/L (n=10 144) RR 0.86 (0.78–0.93)c
 Serum 25(OH)D ≥25 nmol/L (n=39 167) RR 0.94 (0.90–0.99)
DIPART, 201020 (n=68517)
Vitamin D alone HR 1.01 (0.92–1.12)
Vitamin D with calcium HR 0.92 (0.86–0.99)
Hip fracture
Boonen, 200722
Vitamin D alone (n=9083) RR 1.10 (0.89–1.36)d
Vitamin D with calcium (n=45 509) RR 0.82 (0.71–0.94)
Avenell, 200521
Vitamin D alone (n=18 668) RR 1.17 (0.98–1.41)
Vitamin D with calcium (n=10 376) RR 0.81 (0.68–0.96)
*   Bold denotes statistically significant, 95% CI does not  
include 1.00; RR = relative risk; HR = hazard ratio
a.   No statistically significant difference in effect between the 
two groups, but a statistically significant effect was only 
seen in with calcium and vitamin D combined
b.  p=0.03 for difference between <800 IU and ≥800 IU studies
c.   p=0.06 for difference between <25 nmol/L and  
≥25 nmol/L groups
d.   Indirect comparison gives an RR reduction of 25% for  
vitamin D with calcium vs vitamin D alone (p=0.021)
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the studies in the meta-analysis discussed were for primary fracture 
prevention, ie. prevention of the first osteoporotic fracture, with the 
exception of the REcoRD study.23 this four-arm, secondary prevention 
trial compared vitamin D3 (800 iu/day), 1000 mg calcium, vitamin D3 
(800 iu/day) with calcium (1000 mg/day) and placebo in 5292 mobile 
people (85% female) aged >70 years who had already sustained a low-
trauma fracture. the incidence of new, low-trauma fractures did not 
differ significantly between groups. compliance with treatment was 
low in this study (<50% people took tablets on >80% of days), but even 
in those participants with >80% compliance, no effects were seen. 
REcoRD demonstrates that calcium and vitamin D are insufficient 
by themselves for secondary fracture prevention. however, calcium and 
vitamin D still have an important role in secondary fracture prevention 
as an adjunct to specific anti-osteoporosis therapies. most such 
therapies (eg. bisphosphonates) have been evaluated in the context 
of adequate vitamin D levels and calcium intake. in a retrospective 
observational study in 1515 postmenopausal on anti-resorptive 
therapies (alendronate, risedronate and raloxifene), the women who 
were vitamin D deficient (serum 25(oh)D ≤50 nmol/l) were more likely 
to sustain a fracture that those who were vitamin D replete (adjusted 
odds ratio 1.77; 95% ci: 1.20–2.59; p=0.004). therefore optimal vitamin 
D levels seem necessary to maximise the anti-fracture efficacy of 
anti-resorptive agents.24 no studies have similarly investigated the 
impact of calcium repletion on fracture outcomes. however, calcium 
supplementation, in addition to vitamin D and alendronate in healthy 
postmenopausal women with low BmD with a dietary calcium 
intake of ≥800 mg/day did not result in any added benefit for BmD,25 
indicating that providing additional calcium to this population is not 
necessary. significant questions have been raised about the safety 
of calcium supplements due to possible increases in cardiovascular 




intake cannot be attained, and 
•	 that	vitamin	D	supplementation	is	essential	if	vitamin	D	levels	are	
inadequate.11  
Adverse effects of vitamin D: caution 
required with mega-dose therapy 
until recently, the adverse effects of vitamin D were predominantly 
considered to be those of relatively acute toxicity with associated 
hypercalcaemia; namely nausea, vomiting, constipation, anorexia, 
apathy, headache, thirst, sweating and polyuria. there is also a risk of 
renal and cardiovascular damage through ectopic calcification, especially 
in the presence of hyperphosphataemia.27 however, such effects are 
typically seen only at very high doses of vitamin D – suggested to be in 
excess of 25 000 iu/day with corresponding 25(oh)D levels of about 500 
nmol/l2 and are highly unlikely with normal therapeutic doses.
more recently, other safety concerns have emerged with 
less extreme levels of serum 25(oh)D/vitamin D doses. notably, 
mega-dose intermittent oral vitamin D3 (500 000 iu once per year 
in autumn) has been associated with a higher risk of both falls 
(incidence RR 1.15; 1.02–1.30; p=0.03) and fractures (incidence RR 
1.26; 95% ci: 1.00–1.59; p=0.047).18 this was reported in a double-
blind, placebo-controlled Rct of a single annual dose of 500 000 
iu of vitamin D3 administered orally each autumn to winter for 3–5 
years in 2256 community-dwelling older women aged 70 years or 
older and considered to be at high risk of fracture. For both falls 
and fracture, the greatest risk was seen in the first 3 months after 
dosing. this coincided with the substantial increase in serum vitamin 
D levels seen after each dose. serum 25(oh)D was measured in 
a subsample of 137 participants. the median serum 25(oh)D rose 
from 49 nmol/l to approximately 120 nmol/l 1 month after taking 
the vitamin D supplement and at 3 months serum 25(oh)D remained 
high (approximately 90 nmol/l). moreover, a quadratic relationship 
was seen between changes in hip flexion strength and the percent 
change in serum 25(oh)D. At vitamin D increases of less than 100%, 
hip strength increased but with vitamin D increases above this level 
(equivalent to 120 nmol/l), hip flexion strength decreased, providing a 
potential mechanism for the increased risk in falls and fractures. 
in general, vitamin D3 supplements in Rcts (predominantly in 
elderly women in institutions and dependent care) are associated 
with lower mortality.28 however, of concern is the indication of a 
u-shaped relationship for serum vitamin D with mortality. A 50% 
higher total mortality rate has been observed in older men living in 
the netherlands, in the lowest 10% of the distribution of plasma 
25(oh)D (<46 nmol/l) as well as the highest 5% (>98 nmol/l) of the 
distribution.29 
Preventing vitamin D deficiency: 
population advice
For most adults in Australia, dietary sources provide only a small 
(5–10%) part of their vitamin D requirement. the main source of 
vitamin D is exposure of the skin to sunlight (uV light). Advice to 
promote some sun exposure to allow the skin to manufacture vitamin 
D3 is important to maintain adequate serum 25(oh)D levels in the 
general community. this advice may be particularly important to 
individuals with known low levels of sun exposure who may need to 
make a particular effort to achieve some exposure to sunlight (eg. 
indoor workers). 
the minimal erythemal dose (mED) is the amount of uV exposure 
that just causes faint erythema. this varies with latitude, season, 
time of day, clothing and skin pigmentation. the current vitamin D and 
health in adults in Australia and new Zealand position statement1 
provides a guide for sun exposure times (minutes) which result in 
one-third mED for people with moderately fair skin at times of day 
that are useful for making vitamin D in different regions. if people 
expose around 15% of body surface (arms and hands or legs) for this 
amount of time on most days, this should be equivalent to around 
1000 iu/day of vitamin D3. however, importantly, sun exposure advice 
has to be tempered with the need to avoid excessive sun exposure 
FOCUSVitamin D and the musculoskeletal health of older adults
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hours a day during weekends and holidays).3 As a result, specific 
recommendations for tasmania were developed (see factsheets at 
www.cancertas.org.au/healthy-living/sunsmart) particularly drawing 
attention to times of year where the uV index is moderate (late 
summer to early autumn and early to mid spring) because vigilance 
during this period can reduce the winter dip in vitamin D levels, 
which is of particular importance in tasmania. 
Modifications of advice for at risk groups
Vitamin D deficiency is common in the elderly. the prevalence of 
deficiency defined as serum 25(oh)D <50 nmol/l in a community 
dwelling population-based sample of people over the age of 50 
years in tasmania was 45%.36 some elderly populations are at 
higher risk of vitamin D deficiency and potentially of poor bone 
health as a result of this deficiency. this includes elderly and/
or disabled people in low and high level residential care;37 dark-
skinned people,38 particularly migrants or if modest dress is worn;38 
people with a disability or chronic disease, eg. multiple sclerosis;3 
fair-skinned people and other people at risk of skin cancer who 
avoid sun exposure.39 For example, 86% of women and 68% of 
men in a sample of older people in residential aged care facilities 
in the northern sydney area had a serum 25(oh)D level <28 
nmol/l.40 tailoring of sun exposure advice according to the specific 
requirements of these groups may be necessary. in particular, for 
dark-skinned individuals the duration of sun exposure to achieve 
adequate vitamin D levels is 3–6 times that described for fair-
skinned people. in other high risk groups, eg. elderly in residential 
care,41 people with skin cancer or with conditions resulting in 
photosensitivity, increases in sun exposure may not be safe or 
feasible and supplements may be needed.
Who to test? 
Population screening for vitamin D deficiency in older adults by 
measuring serum 25(oh)D is not recommended, but testing high risk 
groups is appropriate. this includes people with known osteopenia 
and primary or secondary osteoporosis and the at risk groups 
described. if access to testing is a substantial barrier to seeking 
associated with increased skin cancer risk. current cancer council 
recommendations are that most Australians need sun protection to 
prevent skin cancer when the uV index is 3 or above.30 
Sun exposure guidelines for the 
general population
suggested sun exposure guidelines for moderately fair-skinned 
individuals who are not otherwise at increased risk of skin cancer 
are given in Table 3. in summer, vitamin D levels are likely to be 
exposing the hands, face and arms for 6–7 minutes mid-morning 
or mid-afternoon on most days. in winter, advice is more complex, 
depending on latitude. in the far north of Australia, the uV index 
remains moderate to high throughout the year, remaining as high as 
7–8 in June in Darwin for example,31 and unprotected sun exposure 
around noon should be avoided year round. in winter in Brisbane, 
sun exposure at times further from noon may result in a lower 
production of vitamin D. however, while the uV index around noon 
may be above 3,31 the gap between the time needed to gain one- 
third mED (11 minutes) and the time for clearly hazardous levels of 
sun exposure (1 mED) (34 minutes) is higher in winter.32 therefore 
for most people, the short length of exposure required at noon for 
adequate vitamin D production (as given in Table 3) will be low risk.  
in winter in southern Australia, sun exposure at midday for 15–29 
minutes (depending on latitude) with as much bare skin exposed as 
feasible, on most days, is likely to be helpful.1 Exposing more skin in 
winter will increase vitamin D production.33 
While one would expect broad spectrum sunscreens to reduce 
vitamin D production by blocking uV radiation, this may not prove 
to be the case in practice,34 possibly due to inadequate application. 
to maximise vitamin D production for the limited periods of sun 
exposure given in Table 3, use of sunscreen may not be necessary, 
but otherwise appropriate sun protective behaviours should be 
applied.
these guidelines may not guarantee sufficiency in everyone. 
For example, in tasmania the prevalence of vitamin D deficiency 
(≤50 nmol/l) was still 43% among the subgroup of healthy 
adults who were most sun seeking (reported sun exposure of >4 
Table 3. Sun exposure guidelines – Australia
Season and location Advice
Summer (all latitudes) Hands, face and arms exposed for 6–7 minutes mid-morning or 
mid-afternoon on most days
Winter 
Northern Australia, eg. Darwin, Cairns, Townsville Hands, face and arms exposed for 9–13 minutes mid-morning or 
mid-afternoon on most days35
Central Australia, eg. Brisbane, Perth Hands, face and arms exposed for 11 (Brisbane) to 15 (Perth) 
minutes around noon on most days
Southern Australia – Sydney to Hobart Exposure of as much bare skin as feasible around noon most days. 
Duration dependent on latitude – from 16 (Sydney) to 29 minutes 
(Hobart)
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treatment, it may be justified to treat adults who are at very high 
risk of vitamin D deficiency without testing to confirm deficiency. 
in this situation, it is suggested that the same dose used to treat 
moderate to severe deficiency is given.1 
there is the potential for significant variability in test results, 
especially between laboratories, and at the analytically important 
range (<50 nmol/l) of the assay. clinicians should be aware of the 
imprecision of current 25(oh)D testing and exercise caution when 
interpreting results in clinical practice. 
Correcting vitamin D deficiency
mild vitamin D deficiency may be corrected with increased sun 
exposure. however, where this is not possible or feasible, or in the 
case of moderate to severe deficiency, correction is best achieved by 
the use of vitamin D supplements. one suggested regimen is 3000–
5000 iu vitamin D3 daily for 6–12 weeks, checking levels after 12 
weeks. most people will need ongoing treatment at a maintenance 
dose of 1000–2000 iu/day. if this does not correct deficiency, rule 
out underlying gastrointestinal disorders such as coeliac disease.   
higher intermittent doses of vitamin D have been used and will 
correct deficiency. this may be useful where adherence to treatment 
is a major problem. however, such preparations (containing 50 000 
iu vitamin D3) are not routinely available in Australia and prescribing 
permission needs to be obtained from the therapeutic Goods 
Administration (see www.tga.gov.au/hp/access-authorised-prescriber.
htm#about) unless they are obtained from compounding chemists, 
although quality control is an issue in this context. safety issues as 
described should also be considered before taking such an approach.
As low calcium intakes and associated hyperparathyroidism 
increases the degradation of vitamin D compounds, a daily intake of 
1000–1300 mg calcium per day, preferably using calcium-rich foods 
should also be encouraged.
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